Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Biomarker Identifies Damaged Brain Wiring After Concussion

By LabMedica International staff writers
Posted on 08 Dec 2015
Mild traumatic brain injury (TBI) or concussion is often defined as a brief loss of normal brain function typically following a blow to the head and is by far the most common form of TBI and frequently does not even receive medical attention.

A brain protein called alpha II-spectrin N-terminal fragment (SNTF), which rises in the blood after some concussions, signals the type of brain damage that is thought to be the source of cognitive impairments, and may be useful as a biomarker of permanent axonal injury. More...


Scientists at University of Pennsylvania School of Medicine (Philadelphia, PA, USA) selected TBI cases to include 18 patients who died acutely following severe TBI, with survival times ranging from six hours to one week. Detailed reports from the diagnostic autopsy and/or forensic reports were available for all cases and indicated a history of a single severe TBI, supported by autopsy findings. TBI cases were compared to material from 16 age/sex-matched controls, acquired at routine diagnostic post-mortem at the same institution. Controls had no documented history of TBI.

Paraffin-embedded tissue from human postmortem studies was subjected to routine histology including hematoxylin and eosin (H&E) staining as well as immunohistological techniques. A synthetic peptide corresponding to the calpain-generated neoepitope in SNTF (CAQQEVY) was conjugated covalently to maleimide-activated Sepharose via the cysteine side chain and the resulting resin used for affinity purification of SNTF-specific antibodies. Adjacent, serial sections were labeled with an antibody reactive for the N-terminal amino acids 66–81 of the amyloid precursor protein (APP). Some sections were coverslipped using fluorescence mounting medium and visualized using a confocal Eclipse Ti microscope (Nikon; Tokyo, Japan).

Immunohistochemistry (IHC) specific for SNTF was compared to that of amyloid precursor protein (APP), the current standard for diffuse axonal injury (DAI) diagnosis, and other known markers of axonal pathology including non-phosphorylated neurofilament-H (SMI-32), neurofilament-68 (NF-68) and compacted neurofilament-medium (RMO-14) using double and triple immunofluorescent labeling. Supporting its use as a biomarker of DAI, SNTF immunoreactive axons were observed at all time points following both human severe TBI and in the model of mild TBI.

Robert Siman, PhD, a coauthor of the study, said, “The study suggests that we may soon have a blood biomarker for concussion akin to the standard blood test used to detect cardiac damage from heart attacks. SNTF in the blood of a concussed individual may provide a specific diagnosis of diffuse axonal injury as well as the process of axonal degeneration. The study was published on November 20, 2015, in the journal Acta Neuropathologica.

Related Links:

University of Pennsylvania School of Medicine 
Nikon 



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.